SABR for Oligometastatic Renal Cell Carcinoma

Overview

Journal Clin Transl Radiat Oncol

Specialty Oncology

Date 2024 Feb 21

PMID 38380117

Authors

Chang David

Ali Muhammad

Udovicich Cristian

Tran Ben

Azad Arun

Au Lewis

Spain Lavinia

Perera Marlon

Siva Shankar

Affiliations

Soon will be listed here.

Abstract

Stereotactic ablative body radiotherapy (SABR) aims to accurately deliver a higher than conventional dose of radiotherapy to a well-defined target tumour incorporating advanced immobilisation and imaging techniques. SABR is an emerging treatment option for primary kidney cancer especially when surgery is contraindicated. Increasingly, SABR is being incorporated into the management of low-volume stage IV kidney cancers to delay the need for systemic therapy or to prolong the duration of ongoing systemic treatment. This review will evaluate the evidence and limitations of SABR for oligometastatic renal cell carcinoma.

Citing Articles

Stereotactic Body Radiotherapy for Renal Cell Carcinoma-A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings.

Villafuerte C, Swaminath A Cancers (Basel). 2024; 16(19).

PMID: 39409955 PMC: 11475850. DOI: 10.3390/cancers16193334.

References

Rowe S, Gorin M, Hammers H, Som Javadi M, Hawasli H, Szabo Z . Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Ann Nucl Med. 2015; 29(10):877-82. PMC: 4666821. DOI: 10.1007/s12149-015-1017-z. View

Franzese C, Marvaso G, Francolini G, Borghetti P, Trodella L, Sepulcri M . The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis. 2021; 38(6):527-537. DOI: 10.1007/s10585-021-10131-w. View

Motzer R, Mcdermott D, Escudier B, Burotto M, Choueiri T, Hammers H . Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022; 128(11):2085-2097. PMC: 9543316. DOI: 10.1002/cncr.34180. View

Zengin Z, Govindarajan A, Salgia N, Sayegh N, Tripathi N, Muddasani R . Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. Eur Urol Oncol. 2023; 6(4):447-450. DOI: 10.1016/j.euo.2022.11.006. View

Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S . Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016; 34(8):1081-6. DOI: 10.1007/s00345-016-1773-y. View

Meyer A, Carducci M, Denmeade S, Markowski M, Pomper M, Pierorazio P . Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted F-DCFPyL PET/CT. Ann Nucl Med. 2019; 33(8):617-623. PMC: 9774684. DOI: 10.1007/s12149-019-01371-8. View

Amini A, Altoos B, Bourlon M, Bedrick E, Bhatia S, Kessler E . Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?. Pract Radiat Oncol. 2015; 5(6):e589-e596. PMC: 4706456. DOI: 10.1016/j.prro.2015.05.004. View

Sagie S, Sarfaty M, Levartovsky M, Gantz Sorotsky H, Berger R, Percik R . RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. Cancers (Basel). 2022; 14(13). PMC: 9265130. DOI: 10.3390/cancers14133127. View

Ernst M, Navani V, Wells J, Donskov F, Basappa N, Labaki C . Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023; 84(1):109-116. DOI: 10.1016/j.eururo.2023.01.001. View

10.

De B, Venkatesan A, Msaouel P, Ghia A, Li J, Yeboa D . Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2021; 129(5):610-620. PMC: 10097479. DOI: 10.1111/bju.15541. View

11.

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

12.

Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I . Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. Int J Radiat Oncol Biol Phys. 2019; 105(2):367-375. PMC: 7647381. DOI: 10.1016/j.ijrobp.2019.07.023. View

13.

Marvaso G, Corrao G, Oneta O, Pepa M, Zaffaroni M, Corso F . Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?. Clin Transl Oncol. 2021; 23(8):1717-1726. DOI: 10.1007/s12094-021-02574-0. View

14.

Muselaers C, Boers-Sonderen M, van Oostenbrugge T, Boerman O, Desar I, Stillebroer A . Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. Eur Urol. 2015; 69(5):767-70. DOI: 10.1016/j.eururo.2015.11.033. View

15.

Hannan R, Mohamad O, De Leon A, Manna S, Pop L, Zhang Z . Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021; 27(24):6716-6725. PMC: 9924935. DOI: 10.1158/1078-0432.CCR-21-2083. View

16.

Ma M, Li H, Gao X, Liu M, Yin H, Yang K . Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients. Curr Oncol. 2022; 29(10):7832-7841. PMC: 9600736. DOI: 10.3390/curroncol29100619. View

17.

Vogel C, Ziegelmuller B, Ljungberg B, Bensalah K, Bex A, Canfield S . Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clin Genitourin Cancer. 2018; 17(2):e345-e355. DOI: 10.1016/j.clgc.2018.07.024. View

18.

Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F . A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer. 2013; 12(1):50-4. DOI: 10.1016/j.clgc.2013.09.008. View

19.

Tang C, Msaouel P, Hara K, Choi H, Le V, Shah A . Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021; 22(12):1732-1739. DOI: 10.1016/S1470-2045(21)00528-3. View

20.

Blum K, Gupta S, Tickoo S, Chan T, Russo P, Motzer R . Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020; 17(12):659-678. PMC: 7551522. DOI: 10.1038/s41585-020-00382-9. View